Table 2.
1. | Additional PK analysis including well-matched non-pregnant controls |
2. | Delineation of PD end points and the impact of pregnancy on these end points |
3. | Exposure and outcome analyses |
4. | Impact of PK and PD alterations in pregnancy on viral resistance |
5. | Attention to the impact of maternal PK and PD alterations on neonatal outcomes |